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(severe NOH; 0.2–3.0). Using utilities from the literature, net
health beneﬁts were calculated for 5%, 10%, 15% and 20%
10-year background risks of cardiovascular events. RESULTS:
The estimated net health beneﬁts for progression to legal blind-
ness for both medications versus UC were positive and declined
with increasing baseline risk of cardiovascular events. The abso-
lute decline in beneﬁt was greater for ranibizumab than for
pegaptanib (0.67 vs 0.10 quality adjusted life years, respectively)
when the background risk of APTC events increased from 5% to
20%. CONCLUSION: As it incorporates both intended and
unintended effects, estimating net health beneﬁts may be more
informative than combining estimates of efﬁcacy with an
unstructured incorporation of adverse event rates. While both
pegaptanib and ranibizumab show positive net health beneﬁts for
AMD, the risk of cardiovascular events is an important consid-
eration when selecting treatment.
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OBJECTIVES: The purpose of the study is to compare results of
Conjoint analysis from 3 studies in ophthalmology with other
standard measures of QoL. METHODS: The 3 choice based
conjoint (CBC) studies included two in people with glaucoma
(N = 109, N = 74) in which the same attributes but a different
presentation order was used, and one in people with Age Related
Macular Degeneration (N = 126). Other QoL measures included
time trade off, VF-14, NEI-VFQ 25 and EuroQoL. RESULTS: In
all 3 studies the top two attributes were ‘reading’ and ‘getting
about outside’. For the two glaucoma studies, lower ranked
attributes changed position under different presentational order.
A simpler version of the conjoint task using only 3 of the 5
attributes was given to selected AMD patients with poor vision
and showed the same rank order of attributes as in the 5 attribute
task. There were very low correlations between individual con-
joint measures and other Qol measures. (e.g. only 2 out of 65
intercorrelations between NEI and conjoint scores reached
p < 0.05). In time trade off, only around 50% of AMD patients
and 20% of glaucoma patients were prepared to trade any
remaining years and in both cases it was those with poorer vision
(Snellen acuity > 6/12) who were willing to trade (p < 0.01). All
studies showed two subgroups of patients with priorities in
‘reading’ and ‘getting about outdoors’. Shifts of attribute prefer-
ence for changing levels of visual acuity and visual ﬁeld occurred
but not changes in rank order. CONCLUSION: Results from 3
studies (2 glaucoma, 1 ARMD) show little relationship between
Conjoint QoL measures and TTO, VF-14, NEI-VFQ 25 and
EuroQoL suggesting they are assessing different aspects of QoL.
EYE—Patient Reported Outcomes
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OBJECTIVES: To determine the time to discontinuation of dif-
ferent glaucoma medications prescribed subsequent to initial ﬁrst
line therapy in the management of ocular hypertension, primary
open angle glaucoma or normal tension glaucoma. METHODS:
A computerized database at the Glaucoma Clinic of Glasgow
Royal Inﬁrmary currently contains complete treatment histories
of 890 patients with ocular hypertension, primary open angle
glaucoma and normal tension glaucoma. In 1999 the database
was populated with retrospective data abstracted from medical
records dating from as early as 1981, with particular attention
paid to the timing and reasons for treatment changes. Since then
the database has been updated prospectively for all patients
treated medically for these conditions. Treatment discontinua-
tions occur due to efﬁcacy failure, side effects, and/or by patient
choice. Kaplan-Meier analysis was used to describe the time to
therapy discontinuation across a range of second-line glaucoma
treatments without controlling for reason. The number and per-
centages of discrete treatment episodes with each drug exceeding
12, 36, and 60 months duration were determined. Each subject
may have contributed more than one episode over the observa-
tion period. RESULTS: Overall, persistency on Xalacom was
higher than all other drugs at all three time points with 82.7%;
67.6%; and 64.2% (n = 363) of the episodes exceeding 12, 36,
and 60 months in duration respectively. Corresponding persis-
tency rates for other therapies were: Cosopt (the only other ﬁxed
combination in the study) 66.5%; 55.6%; 49.0% (n = 495);
Alphagan 47.6%; 24.0%; 15.0% (n = 601); Azopt 76.4%;
57.9%; 52.5% (n = 304); Betoptic 51.2%; 25.8%; 13.4%
(n = 117); Lumigan 74.0%; 53.6%; N/A (n = 108); Timoptol
0.5% LA 51.2%; 19.9%; 6.6% (n = 123); Travatan 55.5%;
50.1%; 50.1% (n = 69); Trusopt 53.7%; 26.8%; 12.2%
(n = 281); Xalatan 76.8%; 54.6%; 47.5% (n = 944). CONCLU-
SION: Persistency rates at 12, 36, and 60 months were higher for
Xalacom than other medications when used as subsequent
therapy.
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OBJECTIVES: To evaluate the persistence degree (period of time
with continuous medication intake) of glaucoma patients with
monotherapy prostaglandins treatment (latanoprost, bimato-
prost, travoprost). METHODS: An interim analysis of an obser-
vational and retrospective study was performed; 99 patients
(from 4 ophthalmology services) were included and followed
through a period of 24 months, studying the moment in which
patients drop out of treatment. Needed parameters were
obtained from medical records. A descriptive analysis, a Kaplan-
Meier survival analysis and a Cox regression model were carried
out, in order to determine: ﬁrstly, the antiglaucoma agent that is
related with a higher persistence degree; and secondly, to detect
those variables that involve a signiﬁcant variation on the persis-
tence of these patients. RESULTS: In both the descriptive analysis
and the survival curves, latanoprost was associated with a higher
persistence degree in the glaucoma treatment: 81% vs. 43.9% for
bimatoprost and travoprost (p < 0.0003). The persistence degree
was signiﬁcantly inﬂuenced by the following variables: the anti-
glaucoma agent used as monotherapy, with a 3-times higher
hazard of treatment withdrawal during the follow-up period due
to receiving a travoprost or bimatoprost treatment instead of a
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treatment with latanoprost (p < 0.001); and the existence of oph-
thalmologic comorbidities, also with a 3-times higher hazard of
treatment withdrawal in patients that suffer an additional oph-
thalmic pathology (p < 0.007). The main reasons for treatment
drop-out were lack of efﬁcacy and the existence of intolerance
and/or adverse events, numerically superiors in the bimatoprost
and travoprost group. CONCLUSION: Latanoprost shows a
higher persistence degree vs. travoprost and bimatoprost in
routine clinical practice.
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OBJECTIVES: This controlled cross-sectional observational
study was conducted in 4 EU countries and Canada to assess the
burden of bilateral neovascular AMD on patient-reported func-
tioning and health resource utilization (HRU). METHODS: Of
the total 401 bilateral neovascular AMD patients and 471 elderly
non-AMD (control) subjects, 87 and 92 respectively were
French. After recording of Demographic and treatment data,
National Eye Institute Visual Function Questionnaire (NEI VFQ-
25), EuroQol (EQ-5D), Hospital Anxiety and Depression Scale
(HADS), history of falls, fractures and HRU were investigated
through a telephone survey. Comparisons needed chi-square
tests, analysis of variance, and multivariate regression models.
RESULTS: Mean age of AMD patients was 79 and 64% were
female. Comparisons were adjusted for age, gender, and comor-
bid diseases. The mean (95% CI) NEI VFQ overall scale scores
was 44.4 (36.2, 52.6) in AMD patients, vs 91.8 (86.2, 97.5) for
controls p < 0.0001. AMD patients also differed on the HADS
scales: anxiety score: 8.5 (6.3, 10.8) vs. 5.1 (3.5, 6.7),
p = 0.0005; depression scores: 7.1 (5.1, 9.1) vs. 2.9 (1.5, 4.4),
p < 0.0001. A negative trend is observed on EQ-5D: 0.6 (0.5,
0.7) vs. 0.7 (0.6, 0.8), p = 0.0893. In addition, 11.5% of AMD
patients fell in the past 12 months vs 3.3% of controls,
p = 0.053. Furthermore 41.4% of the AMD patients received
assistance for daily activities vs 6.5% of controls, p < 0.0001.
CONCLUSION: Bilateral AMD patients in France reported sub-
stantially worse QOL, poorer vision-related functioning, and
more anxiety and depression symptoms compared with a control
group.
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OBJECTIVES: To adapt the Glaucoma Symptom Scale (GSS) to
Iberian Spanish, and to study the psychometric properties of the
new version. The GSS scale is composed by 10 items, measuring
impact of glaucoma symptoms. Items should be answered for
both eyes. METHODS: An expert panel composed of two oph-
thalmologists, one gerontologist, two methodologists and one
pharma-economist supervised the adaptation procedure. Two
samples were recruited, one composed by 16 patients used to
check comprehension of the ﬁrst version, and 100 sample used
to obtain psychometric estimates. Patients were recruited in
Madrid, Zaragoza and Barcelona. Psychometric properties were
assessed for each eye and for between eyes average scores. Item
analysis, exploratory factor analysis and reliability estimates
were obtained. RESULTS: Patients ranged from 57 to 89 years
old and 50% were female. Symptoms were selected by 30% to
51% of patients, with a slight lower (p = 0.09) presence of symp-
toms in the right eye (mean = 4.3, SD = 3) than in the left eye
(mean = 4.6, SD = 3.1). A high correlation in the number of
symptoms present in each eye was found (r = 0.84, p < 0.001).
The scale could match the original proposed structure of a
functional domain and a non visual ocular symptom domain,
explaining 53% of available variance, but two items “tearing”
and “halos around lights” don’t exhibit high loadings. A three
dimensional structure would exhibit a better ﬁt. Dimensions
show mild correlations (0.14–0.36). Internal consistency is good
(Cronbach alpha = 0.82) and correlation between odd and even
items is moderate 0.653. Content validity was ensured by the
original researchers work. CONCLUSION: The Spanish version
of the GSS questionnaire shows acceptable psychometric prop-
erties. The two dimensional solution is supported although it
does not explain properly all symptoms. Further validity evi-
dences should be collected with special concern on screening
properties and responsiveness should be also evaluated.
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OBJECTIVES: The SF-36, a generic health-related quality of life
measure, comprises 8 domains (Ware 2000) for which physical
and mental component summaries (PCS and MCS) can be
derived (Ware, Kosinski 2001). Until now, no MID for the SF-36
domains and summary scores have been reported for patients
with active Crohn’s disease (CD). Our aims were to determine
the MID for SF-36 using data from the PRECiSE 1 trial (Sand-
born et al. 2006), and to use these MIDs for the interpretation of
results from the PRECiSE 2 trial investigating certolizumab pegol
maintenance treatment (Schreiber et al. 2005). METHODS:
SF-36 MIDs were estimated by anchor-based methods using
known meaningful changes in reference measures (Inﬂammatory
Bowel Disease Questionnaire [IBDQ] and CD Activity Index
[CDAI]). The a priori approach was to select the SF-36 MID
according to the most correlated anchor. Agreement of the
anchor-derived MIDs with results obtained using Standardised
Effect Sizes, Standard Errors of Measurement and Standard
Errors of the Difference was also evaluated. RESULTS: The two
anchors gave similar values of meaningful changes. The IBDQ,
which correlated most closely to SF-36 score changes, was
selected to derive the SF-36 MIDs. Results obtained with other
methods were in agreement with these derived MIDs and were
representative of small to moderate changes (effect sizes ranging
from 0.2 to 0.5). Based on these calculations, it was shown that
a signiﬁcantly higher proportion of patients showed a clinically
meaningful response in the SF-36 PCS and MCS after certoli-
zumab pegol maintenance treatment compared to patients
receiving placebo. CONCLUSION: A multi-faceted approach to
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